Last updated: June 3, 2026
Fabior suppliers: who manufactures, supplies, and distributes tazarotene products in the US and key markets
Fabior is the brand name for tazarotene (topical retinoid) indicated for plaque psoriasis and acne (depending on labeling and strength). Supplier mapping hinges on two layers: (1) the drug product manufacturer listed to FDA for the approved NDA (and any authorized distributors) and (2) the raw-material and intermediate supply chain for tazarotene and formulation components.
Insufficient information exists in the provided prompt to produce a complete, accurate supplier roster (manufacturers, NDA/ANDA holders, labelers/distributors, and upstream API and excipient suppliers) for “Fabior” across jurisdictions.
What companies supply Fabior (tazarotene topical) in the US?
No source data was provided identifying:
- the FDA labeler/manufacturer for the specific Fabior strengths and dosage forms,
- the NDA holder and contract manufacturers,
- authorized distributors or wholesale labelers tied to Fabior in the US supply chain.
Which distributors are listed for Fabior in the US supply chain?
No distributor/wholesaler labeler data is included in the prompt (for example, FDA SPL labeler entries, NDC directory mappings, or wholesaler listings), so the distributor list cannot be compiled reliably.
Who are the API and intermediate suppliers for tazarotene used in Fabior?
No upstream supply-chain information is provided (no raw API supplier names, no DMF/EDMF linkage, and no credible sourcing references), so an API/intermediate supplier list cannot be generated without fabricating details.
How does Fabior’s supply chain differ by dosage form and strength?
Fabior is commonly referenced as a topical gel, but the prompt does not specify the exact marketed presentation(s) and strengths (which affect:
- contract manufacturing sites,
- NDC-specific supply arrangements,
- and component sourcing tolerances).
Without those specifics and without FDA/NDC inputs, a form-by-form supplier breakdown cannot be completed.
What is Fabior’s regulatory supplier footprint (NDA/CMC manufacturers and labelers)?
A complete answer requires the FDA labeler/manufacturer entries tied to Fabior’s marketed NDCs and (where applicable) the reference to listed facilities in the NDA and CMC supplements. Those records are not included in the prompt.
Which manufacturing sites produce Fabior for wholesale distribution?
This requires inspection-ready data such as:
- NDA manufacturing plant listings,
- facility addresses in FDA SPL,
- and, if relevant, third-party package/labeler assignments.
No facility or site data is provided.
What licensing or distribution agreements affect Fabior supply?
No information is supplied about:
- co-promotion,
- regional licensing,
- authorized distribution agreements,
- or parallel trade controls.
A licensing-based supplier mapping cannot be produced from the prompt.
Are there multiple supplier sources for Fabior due to shortages or recall history?
A shortage or recall-based supplier expansion requires:
- FDA recall/shortage records,
- NDC-level lot-level traceability,
- and timeline data.
No such records are included.
Key Takeaways
- A supplier list for “Fabior” requires FDA labeler/manufacturer, NDC-to-facility mapping, and upstream API/ingredient sourcing records.
- The prompt provides no FDA/NDC, NDA holder, manufacturer, distributor, or DMF-linked sourcing inputs.
- Producing a supplier roster without those inputs would require guessing, which cannot be used.
FAQs
- What is the NDA holder for Fabior (tazarotene topical)?
- How do I map Fabior NDCs to the product manufacturer and labeler?
- Which FDA records list manufacturing sites for Fabior?
- How can I identify upstream API (tazarotene) suppliers tied to Fabior?
- Do Fabior shortages change the set of contract manufacturers or labelers?
References
No sources were provided in the prompt, so no citations can be listed.
